A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL

Launched by JIANGSU HENGRUI MEDICINE CO., LTD. · May 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Linperlisib, which will be given together with a medication called rituximab, for adults who have a type of cancer known as relapsed or refractory indolent non-Hodgkin lymphoma (NHL). This means the cancer has not improved after previous treatments or has come back after treatment. The main goals of the study are to find out the best dose of Linperlisib, how well it works, and how safe it is for patients.

To be eligible for this trial, participants should have already received at least one prior treatment for their cancer and have been treated with a specific type of therapy known as anti-CD20. They should also have measurable signs of their cancer, which means the doctors can see the tumors on imaging tests. However, patients who have received certain other treatments recently or have certain health issues may not be able to participate. This trial is currently not recruiting patients yet, but when it begins, participants can expect close monitoring and care from the medical team throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients received at least 1 lines of systemic therapy
• • 2. Previously received anti- CD20 treatment
• • 3. Subjects must have at least one bi-dimensionally measurable lesion (nodal site Ldi \> 1.5 cm or extranodal site Ldi \> 1.0cm)
• • 4. Patients must have an acceptable organ function
• Exclusion Criteria:
• • 1. Previously treated with PI3K inhibitors
• • 2. Unresolved toxicity of CTCAE grade \> 1 from prior anti-lymphoma therapy
• • 3. Chemotherapy or other antitumor therapy within 14 days before starting cycle one
• • 4. Significant concurrent medical disease or condition which according to the investigators' judgement
• • 5. Active hepatitis B, C or HIV infection
• • 6. Infection requiring treatment 2 weeks prior to the first dosing